Immuneering Corporation filings document the disclosure record of a late-stage clinical oncology company developing Deep Cyclic Inhibitors for cancer. Recent Form 8-K reports cover operating and financial results, R&D spending, capital resources, and clinical updates for atebimetinib (IMM-1-104), including its evaluation with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
Proxy materials describe annual meeting matters for holders of Class A common stock, including director elections, auditor ratification, board governance and voting procedures. The filing record also includes material-event disclosures addressing material agreements, capital-structure matters, shareholder votes, and regulatory and clinical disclosures for the company’s oncology development programs.
Benjamin J. Zeskind reports beneficial ownership of 4,357,807 shares of Immuneering Corporation Class A common stock, representing 6.6% of the class. This ownership is calculated as of December 31, 2025, based on 64,569,967 shares outstanding as of November 5, 2025, as disclosed in Immuneering’s Form 10-Q. The position includes 2,312,852 shares held directly, 1,150,028 shares underlying stock options exercisable on or before March 1, 2026, and 894,927 shares held by the Benjamin J. Zeskind 2020 Family Trust, for which his spouse is sole trustee. Zeskind has sole voting and dispositive power over 3,462,880 shares and shared voting and dispositive power over 894,927 shares.
Immuneering Corp’s Chief Business Officer, Harold Eugene Brakewood, reported buying Class A common stock. On January 16, 2026, he purchased 5,250 shares of Immuneering’s Class A common stock at a price of $4.76 per share, coded as an open-market or private purchase (transaction code "P").
After this transaction, Brakewood beneficially owned a total of 11,050 shares of Immuneering Class A common stock, held in direct ownership.
Immuneering Corp director Thomas J. Schall reported buying additional Class A common stock. On January 15, 2026, he purchased 21,645 shares of Immuneering Class A common stock in an open-market transaction coded as a purchase. The weighted average price was $4.6681 per share, with individual trades executed through a broker-dealer at prices ranging from $4.61 to $4.69. Following this transaction, Schall directly beneficially owns 74,530 shares of Immuneering Class A common stock.
Immuneering Corp's Chief Scientific Officer, Brett Matthew Hall, reported buying Class A Common Stock in an insider transaction. On January 15, 2026, he purchased 2,298 shares at a weighted average price of $4.57 per share through a broker-dealer.
After this purchase, Hall directly beneficially owns 376,496 shares of Immuneering Class A Common Stock. The trade was executed in multiple lots at prices ranging from $4.57 to $4.571, with the weighted average price reported in the filing.
Immuneering Corp received an updated ownership report from Empery Asset Management and affiliated reporting person Ryan M. Lane. They report beneficial ownership of 3,250,775 shares of Class A common stock, equal to 4.99% of the company’s outstanding shares. This total includes 575,825 shares issuable upon exercise of warrants held by funds managed by Empery.
The percentage is based on 64,569,967 shares of common stock outstanding as of November 5, 2025, as disclosed in Immuneering’s Form 10-Q. The warrants contain a 4.99% “Blocker” provision that prevents the reporting persons from exercising warrants if it would push their beneficial ownership above 4.99% of Immuneering’s outstanding common stock. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Immuneering Corp's Chief People Officer, Leah R. Neufeld, reported buying 2,626 shares of the company's Class A common stock on January 13, 2026. The purchase was recorded at a price of $4.153 per share and is classified as a direct acquisition. After this transaction, Neufeld directly holds 25,970 Class A common shares of Immuneering Corp.
Immuneering Corp director Peter Feinberg reported an indirect purchase of Class A common stock on January 12, 2026. Through S4K Investments LLC, he acquired 20,000 shares at a weighted average price of $4.3452 per share, with individual trade prices ranging from $4.315 to $4.38.
After this transaction, Feinberg beneficially owned 135,441 Class A shares indirectly as general partner of S4K Investments LLC. He also held 156,766 shares directly, plus indirect holdings of 392,242 shares as general partner of PF Associates L.P. and 476,615 shares as general partner of PEF LLC.
Immuneering Corporation reported updated interim results from its ongoing Phase 2a trial of atebimetinib, an oral MEK inhibitor, combined with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer. In the initial intent-to-treat group of 34 patients treated at 320 mg once daily, 12‑month overall survival was 64% as of a December 15, 2025 cutoff, compared with 35% reported for standard of care in the MPACT trial. Median overall survival has not yet been reached, and median progression-free survival was 8.5 months.
Six‑ and nine‑month overall survival in this group was 94% and 83%, respectively, versus 67% at six months and an estimated ~47% at nine months for standard of care, based on MPACT data and company extrapolations. The combination was generally well tolerated, with Grade ≥3 treatment-emergent adverse events of anemia and neutropenia each in 18% of patients, no Grade 5 events, and no new safety signals. Immuneering outlined plans in 2026 to present additional circulating tumor DNA data, provide updated survival data from over 50 first-line pancreatic cancer patients, start a pivotal Phase 3 trial in first-line pancreatic cancer, and begin a trial with atebimetinib plus Libtayo in non-small cell lung cancer.
Immuneering Corp$6.58 per share, granted on 01/01/2026 and expiring on 01/01/2036.
Under the program, Keating elected to take this stock option instead of a cash base retainer. The option vests in four equal installments: 25% of the shares vest after three months of continuous service as a non-employee director, with the remaining installments vesting so that the final portion vests on the first anniversary of the grant date, as long as service continues. Following this grant, 7,888 derivative securities are beneficially owned directly.
Immuneering Corporation (IMRX) filed its Q3 2025 10-Q, highlighting a major balance sheet step-up driven by equity financings. Cash and cash equivalents were $227.6 million as of September 30, 2025, up from $36.1 million at year-end 2024, primarily from a $164.1 million underwritten offering, a $23.3 million private placement with Aventis (Sanofi), a $23.4 million August private placement including pre-funded and purchase warrants, and activity under its ATM program.
Operations remained consistent with development stage activity. Q3 2025 net loss was $15.0 million (loss per share $0.38), with R&D $10.9 million and G&A $4.5 million. For the nine months, the company reported a $44.4 million net loss. Management stated its cash is expected to fund operations for at least 12 months from issuance. The company continues advancing atebimetinib (IMM‑1‑104), including an ongoing Phase 1/2a and a planned registrational trial in first-line pancreatic cancer. Shares outstanding were 64,569,967 Class A as of November 5, 2025.